Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
JANSSEN NZ LIMITED,Fixed duration Ibrutinib plus venetoclax,previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Leukaemia (SLL) patients without TP53 mutation,Fixed duration Ibrutinib plus venetoclax (IMBRUVICA),Recommended for decline,Community and Hospital,
